Conclusion The reliability of the FS methodology was an accurate test to help perform appropriate surgery and plan swift oncological treatment. FS is a reliable method to diagnose invasive malignancies and benign pathology. The communication between the pathologist, surgeon, and medical oncologist is highly important for both intraoperative decision-making and postoperative patient care.

Abstracts

OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA

Introduction/Background

In ARIEL3 (NCT01968213), progression-free survival (PFS) was significantly improved with rucaparib maintenance treatment versus placebo. We present updated PFS2 and preplanned final overall survival (OS) analyses.

Methodology

ARIEL3 enrolled patients with platinum-sensitive, high-grade ovarian carcinoma who had received ≥2 previous platinum-based chemotherapy regimens and had responded to their last platinum-based regimen. Patients were randomised 2:1 to receive rucaparib 600 mg twice daily or placebo, with 3 protocol-defined nested cohorts: BRCA mutant, homologous recombination deficient (HRD) and intent-to-treat (ITT). Efficacy outcomes for the nested cohorts included the secondary endpoint of OS (with analysis planned after 70% of events) and the exploratory endpoint of PFS2 (defined as time from randomisation to second event of investigator-assessed disease progression or death due to any cause). Patients were followed for the incidence of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Data cutoff dates were 31 December 2019 (safety), 4 April 2022 (efficacy) and 12 April 2022 (monitoring of MDS/AML).

Results

After a median follow-up of 77.0 months in the ITT population, 410/564 (72.7%) of OS events had occurred. OS and PFS2 are presented in table 1. A PARP inhibitor was administered as subsequent treatment to ≈45% of patients who received placebo. Safety data were consistent with those of prior reports. MDS/AML was reported in 14 (3.8%) and 6 (3.2%) patients in the rucaparib and placebo arms, respectively (P=0.72). Among these, 8 patients in the rucaparib arm and 6 in the placebo arm developed MDS/AML after completion of study drug treatment.

Abstract 2022-RA-249-ESGO Table 1

<table>
<thead>
<tr>
<th>BRCA</th>
<th>PFS2 events, n (%)</th>
<th>Median PFS2 (months [95% CI])</th>
<th>PFS2 RR (95% CI)</th>
<th>P</th>
<th>OS events, n (%)</th>
<th>Median OS (months [95% CI])</th>
<th>OS RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo</td>
<td>66 (75.0)</td>
<td>14 (10.0)</td>
<td>6.6 (5.1–8.1)</td>
<td>0.67</td>
<td>83 (51.3)</td>
<td>16.0 (9.7–21.6)</td>
<td>0.83</td>
<td>0.23</td>
</tr>
<tr>
<td>rucaparib</td>
<td>54 (20.8)</td>
<td>17 (10.7–21.8)</td>
<td>12.4 (10.4–14.4)</td>
<td>0.67</td>
<td>30 (5.5)</td>
<td>17.9 (10.7–21.6)</td>
<td>0.80</td>
<td>0.28</td>
</tr>
</tbody>
</table>

Abstract 2022-RA-272-ESGO

‘DOUBLE O’ TECHNIQUE OF BOWEL ANASTOMOSIS

Introduction/Background

In hand sewn ileo-ileal anastomosis in a lady undergoing debulking surgery for ovarian cancer. Although no OS benefit was observed, the PFS benefit for rucaparib was maintained through the next subsequent line of therapy.
of corner while suturing. Two delayed absorbable sutures with double ended needle are used for the technique.

**Results** Patient had optimal debulking surgery and the postoperative course was uneventful. She received adjuvant chemotherapy and is disease free for 24 months.

**Conclusion** Surgical skill development is crucial for reducing postoperative morbidity and to achieve optimal debulking. Due to increased use of staplers for bowel anastomosis in recent decades, hand sewn bowel anastomosis is not practiced regularly. However, hand sewn anastomosis is cost effective and is especially useful in resource limited or emergency setting. ‘Double O’ technique is simpler to use and eliminates many technical nuances described in traditional hand-sewn anastomosis. The technique helps the gynecological oncology surgical trainee to learn and retain the steps due to its simplicity and also helps to overcome the fear of suturing corners in bowel anastomosis during the learning curve.

---

**2022-RA-275-ESGO**

**COMPARISON OF PATIENTS WITH TRUCUT VALUE OF SURGICAL CYTOREDUCTION FOR OVARIAN CANCER**

Fatma Basak Tamoglu, Caglar Cetin, Gurkan Kiran. Bezmialem Vakif University, Istanbul, Turkey.

10.1136/ijgc-2022-ESGO.490

**Introduction/Background** Ovarian cancer ranks 4th among the deadliest cancers in women and has the highest mortality rate among all gynecological malignancies. In women who are believed to have ovarian cancer but have poor performance status or have advanced disease believed to be beyond the scope of primary cytoreductive surgery and whose pathology cannot be obtained before staging surgery, NACT can be given to patients with acid cytology and/or tru-cut biopsy referral. Our aim is to determine the accuracy, adequacy, safety and reliability of these minimally invasive interventional procedures.

**Methodology** This is a retrospective analysis of 63 patients with a prediagnosis of ovarian cancer in our hospital between 2014 and 2021, who underwent ultrasound-guided acid cytology and tru-cut biopsy, and also had postoperative final pathology results.

**Results** When the pathology results of the patients who received acid cytology, tru-cut biopsy, acid cytology and tru-cut biopsy at the same time were compared with the postoperative final pathology results, it was seen that the PPV was 100% in all groups. It was revealed that the sensitivity of acid cytology was 64%, the specificity was 100%, the NPV was 12%, and the accuracy of the test was 65%. The sensitivity of the Tru-cut biopsy was 91%, the specificity was 100%, the NPV was 42%, and the accuracy of the test was 92%. In the case of both procedures, the sensitivity was calculated as 93% and the accuracy of the test was calculated as 93%. There were no false positive cytology and biopsy results that could lead to unnecessary NACT therapy in the study. 97 minimally invasive procedures were performed under ultrasound guidance.

**Conclusion** Minimally invasive procedures can be safely applied to patients with low complication and high accuracy rates, since they provide NACT in patients who are thought to be candidates for interval surgery.

---

**Abstract 2022-RA-275-ESGO Table 1**

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid cytology</td>
<td>9/64</td>
<td>9/100</td>
<td>9/100</td>
<td>9/12</td>
<td>9/68</td>
</tr>
<tr>
<td>Tru-cut biopsy</td>
<td>9/61</td>
<td>9/100</td>
<td>9/100</td>
<td>9/62</td>
<td>9/65</td>
</tr>
<tr>
<td>Acid cytology + tru-cut biopsy</td>
<td>9/65</td>
<td>YOK</td>
<td>YOK</td>
<td>YOK</td>
<td>YOK/93</td>
</tr>
</tbody>
</table>

---

**2022-RA-276-ESGO**

**VALUE OF SURGICAL CYTOREDUCTION FOR SUBSEQUENT OVARIAN CANCER RELAPSE IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY ALONE AT 1ST-RELAPSE: A SUBANALYSIS OF THE DESKTOP III/ ENGOT-OV20 TRIAL**

1Christina Fotopoulou, 2Jalid Sehouli, 3Ignace Vergote, 4Alexander Reuss, 5Marianne Leheurteur, 6Felix Hilpert, 7Aude-Marie Savoye, 8Stefano Greggi, 9Johanna Vemerson, 10Benidt Resch, 11Michel Gatineau, 12Jean Levillque, 13Rongyu Zang, 14Pernille T Jensen, 15Jae W Kim, 16Domingo Santiago, 17Francesco Raspagliesi, 18Ulla Peen, 19Andreas du Bois, 20Philip Hartes, 21AGO and Imperial College, London, UK; 22AGO and Campus Virchow, Charité, Berlin, Germany; 23BGOG and University Hospitals Leuven, Leuven, Belgium; 24Coordinating Center for Clinical Trials, AGO and Philips-University Marburg, Marburg, Germany; 25GINECO and Centre Henri Becquerel, Rouen, France; 26AGO and Oncologisches Therapeutzentrum Krankenhaus Jerusalem, Hamburg, and UKSH Kiel, Hamburg, Germany; 27GINECO and Institut Jean Godinot, Reims, France; 28Mito and Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Milano, Italy; 29NSGO-CTU and Karolinska University Hospital, Clinical Trials Unit Solna, Solna, Sweden; 30AGOG and CHU de Rouen, Rouen, France; 31GINECO and Hospital St Joseph, Paris, France; 32GINECO and CHU Rennes, Rennes, France; 33Fudan University Zhongshan Hospital, Shanghai, China; 34NSGO-CTU and Odense University Hospital, Gynecology and Obstetrics, and Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark; 35KOGO and Seoul National University, Seoul, Korea, Republic of; 36GINECO and Hospital Universitari i Politecnic La Fe, Valencia, Spain; 37Mito and Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy; 38NSGO-CTU and Herlev University Hospital, Herlev, Denmark; 39AGO and Ev. Kliniken Essen-Mitte, Essen, Germany.

10.1136/ijgc-2022-ESGO.491

**Introduction/Background** The DESKTOP III trial has demonstrated a significant survival benefit in AGO-score positive patients who underwent complete cytoreduction at 1st relapse compared to those treated with chemotherapy alone. The question whether eligible patients who missed the opportunity of potentially life prolonging surgery at 1st relapse would benefit from surgery at the time of their second relapse, remains open.

**Methodology** We evaluated separately the patients who were randomized in the standard, non-surgical arm of the DESKTOP III trial who then subsequently underwent cytoreductive surgery at a subsequent relapse at investigator’s discretion.

**Results** The median progression-free survival (PFS) counted from randomization of 201 patients in the control arm of DESKTOP III was 14.0 months. 171 (85%) had progressive or relapsing disease and 32 of 171 (19%) underwent cytoreductive surgery. Patients’ median age at this subsequent surgery was 63 years (range: 46 – 78). Complete tumor resection was